Ensuring Pull Incentives for Priority Antibiotics Succeed

Duke-Margolis Center for Health Policy

Webinar Agenda  |  November 17, 2021  |  12:00 – 2:00 pm ET

12:00 pm  Welcome and Opening Remarks
Mark McClellan, Director, Duke-Margolis Center for Health Policy

12:10 pm  Session 1a: Tailoring Pull Incentives to Sustain Priority Antibiotic Development
This session will highlight recent modeling that can inform how policymakers tailor pull incentives for priority antibiotics according to varied but predictable parameters including developmental costs and durations, probabilities of success, and expected revenues. Policymakers can tailor the magnitude and features of proposed pull incentives, like the PASTEUR Act, to secure future novel antibiotics that are valuable and reduce the burden of drug-resistant infections.

Presentation – Sizing Global Antibacterial Pull Incentives

- Kevin Outterson, Boston University

Panelists will explore how to:

- Communicate evidence indicating that pull incentives are likely to succeed
- Design appropriate pull incentives considering assumptions and limited data

Panel Discussion

- Cornelius J. Clancy, University of Pittsburgh
- Joseph Larsen, Venatorx Pharmaceuticals
- Monique K. Mansoura, The MITRE Corporation
- Kevin Outterson, Boston University
- Arjun Srinivasan, U.S. Centers for Disease Control and Prevention

12:50 pm  Session 1b: Advancing Pull Incentives Through Administrative Action
This session will explore administrative actions that can bolster public health preparedness and advance payment models that complement pull incentives for priority antibiotics and reduce the cost of future pull incentives.

Panelists from Session 1a will explore how to:

- Leverage HHS and CDC efforts to bolster public health preparedness, including promoting manufacturing and supply chain resilience
- Ensure the domestic manufacturing and commercialization of priority antibiotics is resilient and benefits the sustainability of pull incentives and antibiotic innovation
Leverage stewardship and surveillance goals to drive data capture and evidence development that complements pull incentives for priority antibiotics

*Panel Discussion – Panelists Continue from Session 1a*

### 1:25 pm  
**Session 2: The Need for Pull Incentives Beyond the U.S. and U.K.**

This session will focus on global leadership to incentivize novel antibiotic development and access. Panelists will explore how to:

- Engage G7/G20 leaders to commit to implementing additional pull-incentives
- Support broader access to novel antibiotics among countries beyond the U.S., including low- and middle-income countries (LMICs)
- Ensure appropriate global antibiotic stewardship

*Panel Discussion*

- **Christine Årdal**, Public Health Norway
- **Nick Crabb**, National Institute for Health and Care Excellence (U.K.)
- **Lynn Filpi**, Office of Global Affairs, U.S. Dept of Health and Human Services
- **Caline S. Mattar**, Global AMR R&D Hub & Washington University

### 1:55 pm  
**Closing Remarks**

**Mark McClellan**, Director, Duke-Margolis Center for Health Policy

### 2:00 pm  
**Adjournment**